Limb Preservation Platform Inc — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$2,400	1
2022	Research	$58,243	16
2021	Research	$12,754	2
2020	Research	$46,509	7
2019	Research	$83,826	8

Breakdown

Who paid Research payments · program years 2019–2025

Ipsen Innovation $102,200 9 payments
Endo Pharmaceuticals Inc. $58,243 16 payments
Mallinckrodt Hospital Products Inc. $39,890 7 payments
PolyNovo North America LLC $2,400 1 payment
Celgene Corporation $1,000 1 payment

Studies the money was for Research payments · program years 2019–2025

A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for the Treatment of Pain Associated With Hallux Abducto Valgus $102,200 9 payments
An Open-Label, Prospective, Multicenter, Safety and Tolerability Study of Expressgraft-C9t1 Skin Tissue in the Treatment of Diabetic Foot Ulcers $39,890 7 payments
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis $37,202 10 payments
A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis $21,041 6 payments
Cp-005 Dfu $2,400 1 payment
A phase 2 multicenter, randomized, doubleblind, placebo–controlled, dose range finding study to evaluate the efficacy and safety of intramuscular injection of human placenta-derived cells (pda-002) in subjects who have diabetic foot ulcer with peripheral arterial disease (CCT-PDA-002-DFU-002) $1,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.